# Trade Mark Journal No.2026/021 22 May 2026

## WO0000001891345 (42)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:29 August 2025
Date of designation in the UK: 29 August 2025

International priority date claimed: 29 April 2025 (European Union Intellectual Property Office (EUIPO)) (019179696)

Class 42
  Research and development services in the field of pharmaceuticals and drug discovery; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes; scientific research for medical purposes, namely, screening for the identification of drug candidates; development of precision RNA therapeutics; development of tailored RNA-based corrective interventions to target the root causes of serious diseases; research and development of new medical products for others; development and identification of novel druggable sites for pharmacological intervention using a bioinformatic discovery platform in a wet lab; screening services, bioinformatics services and modelling services to harness natural processes and modulate gene expression through platforms to generate optimized small molecules, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs); designing and implementing multiplexed high-throughput assays to screen for small molecules that modulate RNA processing using bioinformatic tools.

Contera Pharma A/S

Representative: HGF Limited, 4th Floor, 1 City Square Leeds LS1 2ES UNITED KINGDOM